A Study to Evaluate Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

Overview

About this study

The purpose of this study is to investigate if a blood test measuring copeptin within 24 hours following pituitary surgery could predict development of diabetes insipidus (increased urination and thirst with fluid balance problems) as opposed to the clinical methods we currently use.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients 18-95 years old.
  • Diagnosed with sellar and suprasellar masses.
  • Undergo neurosurgical procedure at Mayo Clinic Rochester.

Exclusion Criteria:

  • Patients under 18 or over 95 years old.
  • Patients with preexisting central diabetes insipidus (CDI).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Dana Erickson, M.D.

Open for enrollment

Contact information:

Neurosurgery Research Coordination Staff

(507) 422-2121

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20480305

Mayo Clinic Footer